Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Zercepac 420mg pdr for concentrate for inf vials
0801050ADBHACAE
|
Zercepac | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Zercepac 60mg pdr for concentrate for inf vials
0801050ADBHABAF
|
Zercepac | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Zinbryta 150mg/1ml solution for injection pre-filled pens
0802040AZBBAAAA
|
Zinbryta | Daclizumab (Immunomodulating) | Malignant Disease and Immunosuppression | No data available |
|
Zirabev 100mg/4ml solution for infusion vials
0801050APBCAAAA
|
Zirabev | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Zirabev 400mg/16ml solution for infusion vials
0801050APBCABAB
|
Zirabev | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Zortress 250microgram tablets
0801050AXBEAAAD
|
Zortress | Everolimus | Malignant Disease and Immunosuppression | No data available |
|
Zortress 750microgram tablets
0801050AXBEABAE
|
Zortress | Everolimus | Malignant Disease and Immunosuppression | No data available |
|
Zytiga 250mg tablets
0803042T0BBAAAA
|
Zytiga | Abiraterone | Malignant Disease and Immunosuppression | No data available |
|
Zytiga 500mg tablets
0803042T0BBABAB
|
Zytiga | Abiraterone | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.